Scioderm Sells to Amicus Therapeutics for up to $947 Million

Washington, DC – October 2, 2015 – Cooley advised Scioderm on its sale to Amicus Therapeutics. According to the terms of the transaction, Amicus will pay $229 million in stock and cash along with up to $618 million upon achievement of regulatory and sales milestones and $100 million for a priority review voucher.

Scioderm is a privately held, clinical-stage biopharmaceutical company focused on developing innovative therapies to address diseases with high unmet need, including rare diseases. Amicus Therapeutics is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases.

The M&A team advising Scioderm included partner and head of Cooley's M&A practice, Barbara Borden, partner Christian Plaza, and associates Marc Samuel, Eric Dixon, Alison McCormick and Kerry Killeen.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Kay Chandler Partner, San Diego
Barbara Borden Partner, San Diego
David Walsh Partner, Reston
Christian Plaza Partner, Reston
Natasha Leskovsek Partner, Washington, DC
Lesse Castleberry Senior Counsel, New York
Eric Dixon Associate, Washington, DC
Jacqueline Grise Partner, Washington, DC
Tanisha A. James Partner, New York
Keith Ranta Special Counsel, Washington, DC
Marc Samuel Special Counsel, Washington, DC
Julia Renehan Associate, Washington, DC
Stephanie Gentile Partner, New York